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Direct-To-Consumer Advertising of Prescription Drugs
Abstract
In 2007, the pharmaceutical industry spent more than $4.9 billion on direct-to-consumer advertising
(DTCA) of prescription drugs in the U.S. Controversy over DTCA has grown since the Food and Drug
Administration liberalized its regulations in 1997. Proponents claim that such advertising educates
consumers, promotes patient participation in clinical decisions, and improves patient adherence to
medication instructions. Opponents argue that such advertising is meant to persuade, not educate, and
that it promotes inappropriate use of prescription drugs, or diverts consumers from better alternatives.
This Issue Brief summarizes the evidence about the effects of DTCA, and proposes guidelines for
improving the utility of prescription drug advertising.
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Direct-To-Consumer Advertising of
Prescription Drugs
Editor’s note: In 2007, the pharmaceutical industry spent more than $4.9 billion
on direct-to-consumer advertising (DTCA) of prescription drugs in the U.S.
Controversy over DTCA has grown since the Food and Drug Administration
liberalized its regulations in 1997. Proponents claim that such advertising educates
consumers, promotes patient participation in clinical decisions, and improves
patient adherence to medication instructions. Opponents argue that such
advertising is meant to persuade, not educate, and that it promotes inappropriate
use of prescription drugs, or diverts consumers from better alternatives. This Issue
Brief summarizes the evidence about the effects of DTCA, and proposes guidelines
for improving the utility of prescription drug advertising.

Only the U.S. and New Zealand permit direct marketing of prescription drugs to
consumers. The Food and Drug Administration (FDA) acquired jurisdiction over
DTCA of prescription drugs in 1962. For the next 35 years, television advertising
was limited by the requirement that ads summarize potential adverse reactions and
contraindications to drugs.
• In 1997, the FDA issued guidelines that described how ads could make
“adequate provision” for the full disclosure of risks and benefits by referring
viewers elsewhere, to a toll-free telephone number, concurrent print ad, a web
site, or a physician. As a result, the pharmaceutical industry greatly increased
its spending on DTCA, and shifted the majority of its budget from print to
broadcast media.
• Regulation of DTCA recognizes that prescription drugs differ from other
consumer products because of the drugs’ inherent risks. Nevertheless,
commercial speech is given significant protection under U.S. law, leading
legal scholars to conclude that an outright ban on DTCA would not likely
pass constitutional muster. The question remains about how to balance these
constitutional protections with the need to protect the public’s health.
• American television viewers see as many as 16 hours of prescription drug ads
per year, far exceeding the average time spent with a physician. Pharmaceutical
manufacturers concentrate DTCA spending on a few brand-name drugs,
mostly those used to treat chronic conditions with broad and enduring
potential markets—such as high cholesterol, insomnia, or reduced bone
density. In 2008, the class of drugs with the greatest DTCA spending was
treatments for erectile dysfunction.

Review of evidence focuses
on how DTCA affects
clinical care

Frosch and colleagues reviewed studies published from 1997 to 2009. They judged
the strength of the evidence for each of the competing claims about DTCA.
• Their conceptual framework centered around the consumer as an active
participant in medical decision making. Exposure to prescription drug
advertising can prompt prescription requests, which may be clinically
appropriate or inappropriate. If the request is inappropriate, and the physician
cannot or will not correct the patient’s perception, DTCA may lead to
unnecessary and potentially harmful prescribing. On the other hand, if the
request is appropriate, DTCA may reduce under prescribing and contribute to
patient adherence.
• Exposure to ads may also affect consumer perceptions of treatable illnesses
even if it does not lead to a prescription request. For example, it may prompt
consumers to seek medical attention for undiagnosed symptoms or remind
patients about their prescriptions.

DTCA provides information
that is valued by the public,
but current ads may not
be an effective education
vehicle

DTCA proponents justify the proliferation of ads by citing their educational
potential. Physicians and patients have been surveyed about their perceptions of
drug ads, and the content of print and television ads have been studied.
• In surveys of the public, nearly 75% of respondents believe that ads improve
their understanding of diseases and treatments, and more than 40% report
using ad information when making medical decisions.
• In surveys, more than half of physicians agree that DTCA educates patients
about diseases and treatments. Many physicians, however, believe that DTCA
both encourages patients to make unwarranted requests for medication, and
promotes unnecessary fear of side effects.
• Analyses of the content of ads find that most DTCA lacks information
important to help consumers decide about the benefits and risks of prescription
drugs. Benefits of drugs are often described in vague terms or through narratives
that exaggerate the magnitude of benefits. In print ads, most of the content
exceeds the eighth-grade reading level recommended for the general public.

Effects of DTCA on
physician-patient
communication are
unclear, although it may
reduce undertreatment
and improve patient
adherence in selected
conditions

Studies examining the relationship between DTCA and quality of care have
focused on whether patients exposed to DTCA have better discussions and
relationships with their physicians.
• Surveys of physicians and patients suggest that DTCA promotes patients’
participation in their medical care and gives patients more confidence to discuss
health-related concerns. Patients report making better health decisions and
seeking more information about current and previously diagnosed conditions.
• Evidence concerning the relationship between DTCA and physician-patient
communication is mixed. Most physicians and patients agree that DTCA can
prompt important discussions; however, physicians are less likely to endorse
the positive aspects of DTCA and more likely to worry that DTCA promotes
longer, unnecessary visits and inappropriate medication requests.
• Limited evidence, including some randomized trials, suggests that DTCA may
ameliorate under treatment of selected conditions, such as depression.
• DTCA may have a small beneficial effect on patient adherence. Analyses of
claims data show a small but significant association between DTCA spending
and duration of treatment with antidepressants and cholesterol-reducing statins.

DTCA-prompted requests
increase both appropriate
and inappropriate
prescribing

Critics of DTCA cite its potential to increase inappropriate prescribing, reflecting
both cost and safety concerns.
• Physician surveys find that 81% of respondents believe that DTCA promotes
medication requests, and one-quarter report resulting changes in their
prescribing habits. In one survey, physicians judged half of DTCA-prompted
requests to be clinically inappropriate, although 69% of these requests were
at least partially fulfilled to accommodate patients.
• More rigorous evidence measuring DTCA-prompted prescribing comes from
claims data and from a randomized experiment using standardized patients
(actors). The evidence suggests that DTCA-prompted prescription requests
lead to both appropriate and inappropriate prescribing. Which effect is greater
remains unclear.

DTCA should better
identify candidates for
treatment and provide
better information on
drug risks and benefits

Given the evidence of the risks and benefits of DTCA, Frosch and colleagues
developed guidelines to maximize the utility of the ads while minimizing their
clinical risks. In developing guidelines, Frosch and colleagues proposed three goals
that should guide the content of DTCA.
• Ads should help identify appropriate candidates for treatment. The majority of
ads produced to date provide little information that would allow consumers to
clearly identify whether the advertised product is indicated for them.
• Ads should provide accurate and specific information about the potential
benefits of the advertised drug instead of the current qualitative and emotionladen portrayals that often suggest misleadingly dramatic effects.
• Ads should provide specific quantitative information about the potential risks
associated with the drug. Current ads contain a mismatch between visual
imagery and verbal messages when risk information is presented.

Proposed content
guidelines address
evidence-based concerns

The proposed guidelines distinguish between three target audiences for DTCA:
those with undiagnosed, asymptomatic conditions (such as hypercholesterolemia);
those with undiagnosed symptomatic conditions (such as major depression), and
those with previously diagnosed conditions (such as anemia).
• Previously diagnosed patients can judge whether they are candidates for
the drug by the name of the condition alone, but those with undiagnosed
conditions need more information. Ads targeting undiagnosed, asymptomatic
patients should also present information on the condition’s prevalence, potential
clinical consequences, risk factors, and recommended screening tests; those
targeting undiagnosed patients with symptoms should include information on
the condition’s prevalence, potential clinical consequences, symptoms, and any
valid self-administered screening test available.
• The guidelines call for precise information about absolute risk or symptom
reduction expected from drug treatment, compared to placebo, lifestyle
changes, and alternative drugs. The availability of generic alternatives should
be noted.
• The guidelines call for risk information to be provided in a final separate block
of the ad that is narratively and visually distinct from the rest of the ad, without
background music (to reduce distraction). The pace and density of information
should be similar to the rest of the ad. The magnitude and frequency of risk
should be compared to placebo.

POLICY IMPLICATIONS

In effect, DTCA amounts to an uncontrolled experiment affecting population
health. This review suggests that DTCA has some benefits, but significant
risks are evident as well. Regulators and industry representatives alike should
consider the proposed guidelines for their potential to maximize the utility of
DTCA.
• The proposed guidelines will likely encounter resistance. Some may argue
that existing ads are too short to provide all the suggested information.
However, longer drug ads have been produced and run. Others may argue
that such information should be communicated by the physician, not the
ad. This response ignores the time constraints of the typical physician visit,
which leave little time to address misperceptions induced by DTCA.
• To assess the proposed guidelines’ effect on clinical care and population
health, they should be tested in a trial period followed by careful evaluation
of the changes in ad content.
• Significant gaps remain in the evaluation of the effects of current DTCA
on drug expenditures and population health. Such research would be
aided by making the actual air dates and times in different media markets
publicly available.
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